Chilblains

Overview

• Definition: Chilblains, also known as perniosis, is a localized inflammatory condition of the skin caused by an abnormal reaction to cold, non-freezing temperatures, especially in damp conditions. It typically presents as erythematous-to-violaceous, pruritic, tender, and sometimes painful lesions on acral areas (e.g., fingers, toes, ears, nose) that appear hours after cold exposure and resolve within 1-3 weeks. It is distinct from frostbite, which involves actual tissue freezing.
• Epidemiology: Chilblains is common in temperate climates, particularly in regions with cold and damp winters. It has a higher prevalence in women (ratio 2:1 to 3:1 compared to men) and commonly affects young to middle-aged adults, though it can occur at any age. Individuals with poor peripheral circulation, low body mass index (BMI), Raynaud's phenomenon, and certain autoimmune or myeloproliferative disorders are at increased risk. Familial predisposition can occur.
• Classification:
  • Idiopathic Chilblains: The most common form, where no underlying cause or associated systemic disease is identified.
  • Secondary Chilblains: Associated with underlying medical conditions, including:
    • Connective tissue diseases (e.g., Systemic Lupus Erythematosus (SLE), Sjogren's syndrome, Antiphospholipid Syndrome).
    • Cryoglobulinemia.
    • Anorexia nervosa.
    • HIV infection.
    • Certain myeloproliferative disorders.
    • Genetic predisposition (familial chilblains).

Pathophysiology

• Mechanism: The exact mechanism is not fully understood but involves an aberrant microvascular response to cold exposure followed by rewarming. When exposed to cold, peripheral vasoconstriction occurs to conserve core body heat. In susceptible individuals, the subsequent rapid rewarming leads to an exaggerated and dysfunctional vasodilatory response, or a failure of small arteries/arterioles to adequately dilate, leading to localized hypoxia, endothelial damage, and an inflammatory reaction. This results in capillary and venule leakage, leading to edema and characteristic skin lesions. Histopathology typically reveals perivascular lymphocytic infiltrate, edema, and sometimes features of small vessel vasculopathy, but true vasculitis (fibrinoid necrosis of vessel walls) is usually absent in idiopathic chilblains.
• Risk Factors:
  • Environmental: Prolonged exposure to cold, damp, non-freezing temperatures; rapid changes in temperature; high humidity; inadequate protective clothing.
  • Individual Susceptibility: Female sex, low BMI, sedentary lifestyle, poor peripheral circulation, smoking.
  • Vascular/Rheumatic Conditions: Raynaud's phenomenon, acrocyanosis, peripheral vascular disease, systemic lupus erythematosus (SLE), Sjogren's syndrome, cryoglobulinemia, antiphospholipid syndrome.
  • Medications: Beta-blockers (can exacerbate symptoms), sympathomimetics (rare).
  • Other: Anorexia nervosa, certain viral infections (e.g., "COVID toes" - an inflammatory pernio-like lesion seen in some COVID-19 patients), HIV infection, genetic predisposition.
• Protective Factors: Avoiding prolonged or repeated cold exposure, wearing appropriate warm and dry clothing (especially on extremities), maintaining core body temperature, regular exercise to improve circulation, smoking cessation.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Lesions typically appear 12-24 hours after cold exposure. They are characterized by:
  • Location: Most commonly on distal extremities (fingers, toes), but also ears, nose, heels, lower legs, and thighs.
  • Appearance: Erythematous, bluish-red, or violaceous papules, nodules, or plaques. Swelling is common.
  • Sensations: Intense pruritus (itching), burning, and pain, which can be exacerbated by warmth.
  • Progression: Lesions may progress to blisters (bullous chilblains), ulceration, or crusting in severe cases.
• Early Signs: Initial blanching or pallor on cold exposure, followed by burning, itching, and redness upon rewarming.
• Advanced Signs: Persistent lesions (lasting more than 3 weeks), ulceration, secondary bacterial infection, scarring, or atrophy, particularly with repeated episodes or severe cases.
• Atypical Presentations: Bullous lesions, lesions on unusual sites (e.g., thighs in horseback riders or buttocks), chronic persistent lesions (referred to as chronic perniosis).

Physical Examination

• Inspection:
  • Location: Symmetrical distribution on acral areas (dorsal surfaces of fingers and toes, helix of ears, nose, heels).
  • Morphology: Well-demarcated, edematous, erythematous to violaceous papules, plaques, or nodules. Vesicles, bullae, or ulcers may be present in severe cases.
  • Skin Changes: May show post-inflammatory hyperpigmentation or atrophy after resolution.
• Palpation: Lesions are typically firm, indurated, and tender to palpation. Affected skin may feel cool.
• Special Tests: No specific diagnostic special tests. Assessment of peripheral pulses and capillary refill time helps evaluate overall peripheral circulation and rule out other vascular conditions.

Diagnostic Approach

History Taking

• Key Questions:
  • Detailed history of recent cold and damp exposure: type of exposure, duration, temperature, presence of moisture.
  • Onset, duration, and character of symptoms (itching, burning, pain, color changes).
  • Location and evolution of lesions.
  • History of previous similar episodes and recurrence patterns (chilblains is often recurrent).
  • Presence of Raynaud's phenomenon or other cold sensitivities.
  • Review of systems for symptoms suggestive of underlying systemic disease (e.g., arthralgia, myalgia, fatigue, dry eyes/mouth, photosensitivity, fevers, weight loss).
  • Medication history (e.g., beta-blockers).
  • Smoking history.
  • Personal or family history of autoimmune diseases or circulatory problems.
• Red Flags:
  • Systemic symptoms (e.g., fever, joint pain, muscle pain, weight loss) warrant investigation for underlying autoimmune or systemic conditions.
  • Severe pain, extensive ulceration, or signs of tissue necrosis, which may suggest a more severe underlying vasculopathy or cryoglobulinemia.
  • Asymmetrical lesions or lesions in unusual non-acral locations (may prompt consideration of other differential diagnoses like vasculitis).
  • Lack of clear cold exposure history.

Laboratory Tests

• First-Line: Laboratory tests are generally not required for the diagnosis of typical, idiopathic chilblains based solely on clinical presentation and history.
  • If systemic symptoms are present or an underlying condition is suspected, consider:
    • Complete Blood Count (CBC): To evaluate for anemia, leukopenia, or thrombocytosis (e.g., in myeloproliferative disorders).
    • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Markers of inflammation; may be elevated in secondary chilblains or other inflammatory conditions.
• Confirmatory: No specific laboratory test confirms chilblains. Investigations are aimed at excluding underlying conditions.
  • If secondary chilblains or systemic disease is suspected:
    • Antinuclear Antibodies (ANA) and Extractable Nuclear Antigens (ENA) panel (e.g., anti-dsDNA, anti-Ro/La): To screen for connective tissue diseases like SLE or Sjogren's syndrome.
    • Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibodies: If rheumatoid arthritis is suspected (less common direct association).
    • Cryoglobulins: Essential if cryoglobulinemia (Type I, II, or III) is suspected due to palpable purpura, livedo reticularis, or vasculitic changes; requires specific collection and transport at 37°C.
    • Serum Protein Electrophoresis (SPEP) with immunofixation: To detect paraproteinemia if cryoglobulinemia is positive.
    • HIV testing: In appropriate risk groups or if there are other suspicious clinical features.
• Monitoring: Laboratory tests are not typically used to monitor chilblains directly but may be used to monitor an underlying systemic disease or potential side effects of systemic medications.

Imaging

• Recommended: Imaging studies are not routinely recommended for the diagnosis of chilblains.
• Advanced:
  • Doppler Ultrasound or Arterial Studies: May be considered if there is suspicion of underlying peripheral arterial disease, especially in older patients or those with risk factors (e.g., diabetes, smoking, hyperlipidemia).
  • Nailfold Capillaroscopy: Can be performed to differentiate between primary and secondary Raynaud's phenomenon, which can coexist with chilblains. It may show changes consistent with microangiopathy but is not diagnostic for chilblains itself.
  • Skin Biopsy: Reserved for atypical or chronic lesions, cases refractory to treatment, or when an underlying systemic disease (e.g., lupus pernio, cutaneous vasculitis, specific panniculitis) needs to be confirmed or excluded. Histopathology shows a dense perivascular lymphocytic infiltrate in the superficial and deep dermis, often with papillary dermal edema. Vessel walls are generally intact, differentiating it from true vasculitis.

Management

Acute Management

• Immediate:
  • Gradual Rewarming: Gently rewarm affected areas. Avoid rapid or direct heat sources (e.g., hot water, radiators, fireplaces) as this can worsen tissue damage and pain due to rapid reperfusion injury.
  • Protection: Keep affected areas warm, dry, and protected from further cold exposure. Wear loose, warm, dry gloves, socks, or appropriate protective clothing.
  • Avoid Irritation: Discourage scratching, rubbing, or massaging the affected skin.
• Stabilization:
  • Symptomatic Relief:
    • Topical Corticosteroids: Moderate-potency topical corticosteroids (e.g., triamcinolone acetonide 0.1% cream or ointment) applied 2-3 times daily for 1-2 weeks can reduce itching and inflammation.
    • Analgesia: Over-the-counter NSAIDs (e.g., ibuprofen 400-600 mg every 6-8 hours with food) or acetaminophen for pain relief.
  • Wound Care: For any blistering or ulcerated lesions, standard wound care is essential to prevent secondary infection (e.g., gentle cleansing with saline, application of bland emollient or non-adherent dressing). Topical antibiotics (e.g., mupirocin) can be used if secondary bacterial infection is suspected.
• Emergency: Chilblains is rarely an emergency. However, severe ulceration, necrosis, or signs of severe secondary infection (e.g., cellulitis, gangrene) would warrant urgent medical evaluation and potentially surgical consultation, though this is exceedingly rare for isolated chilblains.

Chronic Management

• Pharmacological:
  • Calcium Channel Blockers (CCBs): Nifedipine is the most evidence-supported systemic medication for recurrent or severe chilblains, primarily due to its vasodilatory effects.
    • Nifedipine (extended-release): Initial dose 10 mg ER once or twice daily, gradually increasing to 20 mg ER twice or three times daily as tolerated. Maximum typical dose is 60 mg/day. Dosing should be individualized. Side effects include headache, flushing, dizziness, and peripheral edema. Contraindicated in severe hypotension or recent myocardial infarction.
  • Topical Nitrates: May be helpful for localized lesions by promoting vasodilation.
    • Topical Nitroglycerin 0.2% ointment: A small amount (e.g., pea-sized) applied to affected areas 1-2 times daily. Potential side effects include localized headache and hypotension.
  • Pentoxifylline: A hemorrheologic agent (improves blood flow by decreasing blood viscosity and improving red blood cell flexibility). Dose typically 400 mg 2-3 times daily. Less evidence than nifedipine for chilblains but may be considered in refractory cases.
  • Systemic Corticosteroids: Generally not recommended for routine management of chilblains due to side effects and limited long-term efficacy. Reserve for very severe, refractory cases or those with significant systemic inflammation potentially related to secondary chilblains, used cautiously and for short durations.
• Non-pharmacological:
  • Strict Cold Avoidance: The cornerstone of management and prevention.
    • Wear warm, loose, layered clothing, especially on extremities (hats, scarves, gloves, wool or synthetic moisture-wicking socks, waterproof boots). Avoid cotton in damp conditions.
    • Maintain warm ambient temperatures in living and working environments.
    • Avoid rapid temperature changes (e.g., moving from a cold outdoor environment directly into a very hot room).
  • Lifestyle Modifications:
    • Smoking cessation: Nicotine is a potent vasoconstrictor.
    • Regular exercise: Improves overall circulation.
    • Avoidance of constrictive clothing/footwear: Can impair circulation.
    • Maintain adequate nutrition: Avoidance of low BMI.
• Monitoring: Clinical assessment of symptom resolution, lesion healing, and prevention of recurrence. If systemic therapy is initiated, monitor for side effects and effectiveness. Annually review preventive strategies before winter.

Treatment Algorithms

• First-Line:
  1. Non-pharmacological Measures: Strict cold avoidance, gradual rewarming, protective clothing, maintaining core warmth.
  2. Symptomatic Relief: Topical corticosteroids (e.g., triamcinolone 0.1% cream BID) and oral analgesics (NSAIDs/acetaminophen) for itching, pain, and inflammation.
• Second-Line:
  • If recurrent, severe, or persistent lesions despite first-line measures:
    1. Systemic Vasodilator: Oral Nifedipine extended-release (ER) 10-20 mg BID-TID.
    2. Consider adding topical nitroglycerin ointment to specific lesions.
• Refractory Cases:
  • Re-evaluate diagnosis and exclude underlying systemic diseases (e.g., SLE, cryoglobulinemia, true vasculitis) with appropriate laboratory tests and/or skin biopsy.
  • Consider alternative systemic agents such as pentoxifylline (400 mg TID).
  • Consult with a dermatologist or rheumatologist.
  • In rare, extreme cases with significant inflammation or ulceration, a short course of low-dose systemic corticosteroids may be considered only after extensive discussion and ruling out other etiologies.

Complications

• Common:
  • Recurrence: Highly common with repeated cold exposure in susceptible individuals.
  • Secondary Bacterial Infection: Due to skin breakdown from scratching or ulceration, leading to cellulitis or impetigo.
  • Post-inflammatory Hyperpigmentation: Darkening of the skin after lesion resolution.
• Serious:
  • Ulceration and Necrosis: More common in severe or protracted cases, or in individuals with significant underlying vascular compromise or systemic disease.
  • Scarring: Can occur following deep ulcerations.
  • Permanent Atrophy or Deformity: Rare, but possible with chronic, severe, or recurrent ulcerating lesions.
• Long-term: Chronic discomfort, pain, itching, and functional limitations can significantly impair quality of life, especially with recurrent episodes. Psychological distress due to visible lesions.

Prognosis

• Factors:
  • Generally Good: Idiopathic chilblains is usually a self-limited condition that resolves spontaneously within 1-3 weeks with warmth and avoidance of cold exposure.
  • Recurrence: While individual episodes resolve, recurrence during subsequent cold seasons is very common if preventive measures are not maintained.
  • Underlying Conditions: The prognosis for secondary chilblains is influenced by the successful diagnosis and management of the associated systemic disease.
• Survival: Chilblains itself is not a life-threatening condition.
• Quality of Life: Can be significantly affected by the discomfort, pain, itching, and functional impairment from recurrent episodes, impacting daily activities and sleep.

Prevention

• Primary: Aimed at preventing the initial occurrence of chilblains.
  • Avoid Cold and Dampness: Stay indoors during very cold, damp weather. Maintain warm indoor temperatures.
  • Wear Protective Clothing: Dress warmly in layers, especially covering extremities. Use hats, scarves, warm, loose-fitting gloves, and wool or synthetic moisture-wicking socks. Wear waterproof and insulated footwear. Ensure clothing is not tight, as this can restrict blood flow.
  • Maintain Core Body Temperature: Keeping the entire body warm helps prevent peripheral vasoconstriction.
  • Regular Exercise: Promotes healthy peripheral circulation.
  • Smoking Cessation: Crucial for improving microvascular circulation.
  • Maintain Healthy Weight: Avoid excessively low BMI.
• Secondary: Focuses on early detection and intervention to prevent worsening of symptoms and lesion progression in susceptible individuals. Promptly rewarm affected areas (gradually) and apply protective measures upon first signs of cold exposure.
• Tertiary: Involves preventing complications such as ulceration and infection in individuals with established chilblains through proper wound care and by implementing systemic therapies (e.g., nifedipine) for those with severe or recurrent disease.

Special Populations

• Pediatric: Chilblains can affect children. Management principles are similar, focusing on warmth, protection, and gradual rewarming. If systemic medication (e.g., nifedipine) is considered, dosing must be carefully adjusted based on age and weight.
• Geriatric: Older adults may have age-related changes in circulation or co-morbidities such as peripheral arterial disease or diabetes, which can predispose them to chilblains or worsen its severity. A thorough vascular assessment is important. Polypharmacy and potential drug interactions should be carefully considered when prescribing systemic agents.
• Pregnancy: Non-pharmacological measures are paramount. While nifedipine is generally considered safe in pregnancy for other indications (e.g., pre-term labor), its use for chilblains should be carefully weighed against potential risks, and maximal non-pharmacological efforts should be made. Consultation with an obstetrician is recommended.
• Comorbidities:
  • Connective Tissue Diseases (e.g., SLE, Sjogren's): Chilblains may be an initial or ongoing manifestation of the underlying disease. Management should include addressing the primary systemic condition.
  • Raynaud's Phenomenon: Patients with Raynaud's are more prone to chilblains. Systemic therapies used for Raynaud's (e.g., CCBs) may also benefit chilblains.
  • Peripheral Vascular Disease: Aggressive risk factor modification and management of PAD are crucial to improve overall circulation and prevent severe complications.
  • Anorexia Nervosa: Nutritional rehabilitation is fundamental to improving overall health and reducing susceptibility.

Clinical Pearls

• Diagnostic:
  • The diagnosis of typical chilblains is primarily clinical, based on a characteristic history of cold exposure followed by pruritic, tender, erythematous-to-violaceous lesions on acral areas.
  • Always differentiate from frostbite (actual tissue freezing) and other conditions causing cold-induced lesions or acral inflammation, such as primary or secondary Raynaud's, acrocyanosis, lupus pernio, cryoglobulinemia, or other forms of vasculitis.
  • If the presentation is atypical, severe, persistent, or associated with systemic symptoms, investigate for underlying systemic diseases.
• Treatment:
  • Prevention through strict cold avoidance and protective clothing is the most effective management strategy.
  • Gradual rewarming is key; avoid rapid, direct heat.
  • Nifedipine is the first-line systemic agent for recurrent or severe chilblains, particularly as a prophylactic measure during cold seasons.
• Pitfalls:
  • Misdiagnosing chilblains as frostbite or vice versa, leading to inappropriate management.
  • Failing to identify and investigate an underlying systemic disease in cases of secondary chilblains.
  • Over-reliance on systemic corticosteroids, which are generally not indicated for idiopathic chilblains.
  • Inadequate patient education regarding preventive measures, leading to frequent recurrences.

Recent Updates

• Guidelines: Current clinical guidelines for chilblains largely reinforce existing recommendations focused on non-pharmacological prevention and the use of nifedipine for severe or recurrent cases. There have been no major paradigm shifts in management.
• Evidence: Recent research has explored the role of specific inflammatory mediators and genetic factors in chilblains pathophysiology. Cases of "COVID toes" during the SARS-CoV-2 pandemic brought renewed attention to pernio-like lesions and their potential viral associations, although the exact mechanism linking COVID-19 to these lesions is still under investigation.
• Controversies: The precise contribution of various inflammatory cytokines and cellular pathways to the pathology of chilblains remains an area of ongoing research. Debates continue regarding the utility of less commonly used pharmacological agents and the optimal approach to very rare, truly refractory cases.

Key References

• Guidelines:
  • While dedicated standalone guidelines for chilblains are rare, recommendations are often found within broader dermatological or vasculitis guidelines from professional organizations such as the American Academy of Dermatology (AAD) or the European Academy of Dermatology and Venereology (EADV).
• Studies:
  • Landmark studies on nifedipine efficacy in chilblains and Raynaud's phenomenon.
  • Recent cohort studies and case series describing clinical features and associations, particularly in the context of emerging infections (e.g., COVID-19).
• Reviews:
  • Comprehensive reviews in leading dermatology journals and textbooks, such as "UpToDate" and major dermatology reference books (e.g., Bolognia, Dermatology; Fitzpatrick's Dermatology in General Medicine).

---

Disclaimer: This information is provided for educational purposes only and is not intended as medical advice. It is crucial for clinicians to exercise independent medical judgment and consider the individual circumstances of each patient. Always consult with relevant specialists and refer to the most current evidence-based guidelines and product information before making any treatment decisions.